A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Clinical trial NCT03849469 · COMPLETED

Trial details

NCT number: NCT03849469
Sponsor: Xencor, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma Cervical Carcinoma Pancreatic Carcinoma Triple Negative Breast Cancer Hepatocellular Carcinoma Urothelial Carcinoma Squamous Cell Carcinoma of the Head and Neck Nasopharyngeal Carcinoma Renal Cell Carcinoma Non-small Cell Lung Carcinoma Small Cell Lung Carcinoma Gastric or Gastroesophageal Junction Adenocarcinoma

Start date: 2019-05-29
Primary completion: 2023-02-16
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.